BriaCell (BCTX) Therapeutics announces that the first patient was dosed in its Phase 1/2 study to evaluate the safety and efficacy of Bria-OTS, BriaCell’s personalized next generation immunotherapy.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback